Awardee OrganizationHUGO W. MOSER RES INST KENNEDY KRIEGER
Description
Abstract Text
The long-term objective of this project is to understand the molecular
pathology and pathogenesis of X-linked adrenoleukodystrophy (ALD), a
fatal neurodegenerative disorder. Defective peroxisomal activation of
very long-chain fatty acids (VLCFA) by very long-chain fatty acyl-CoA
synthetase (VLCS) causes elevated VLCFA levels in ALD patients. The
product of the gene shown to be defective in ALD (ALDP) is a peroxisomal
membrane protein that is a member of the ATP-binding cassette (ABC)
membrane Transporter protein family and does not structurally resemble
Acyl-CoA synthetases. Although ALDP is clearly required for normal
degradation of VLCFA, it does not have VLCS activity, and neither its
biochemical function nor its role in ALD have been elucidated. However,
mutations in this protein lead to devastating clinical pathology. To
develop clinical therapies and to study the pathophysiology of this
disease, both genetic and biochemical studies of ALDP function will be
used. The VLCS gene will be cloned and its gene product characterized
in order to elucidate the relationship of VLCS, previously thought to be
the defect in ALD, to ALDP. Two types of mutagenesis strategies, random
mutagenesis and disruption of specific regions of the regions of the
protein, will be used to analyze the structure and function of ALDP.
Because ABC proteins often require interaction with other proteins for
function, genetic and biochemical approaches will be used to elucidate
ALDP-protein interactions. Finally, the effect of ALDP on VLCFA
metabolism in several cell types (including cells of neural origin) and
in model membranes will examined. These studies will lead to a better
understanding of ALDP function and the precise roles of ALDP and VLCFA
in the pathogenesis of ALD and perhaps provide clues for the phenotypic
variability characteristic of ALD.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
DUNS Number
155342439
UEI
DKMDCB5HNBL7
Project Start Date
01-January-2000
Project End Date
31-December-2000
Budget Start Date
01-October-1998
Budget End Date
30-September-1999
Project Funding Information for 2000
Total Funding
$325,213
Direct Costs
$325,213
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2000
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$325,213
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01HD010981-23 0012
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01HD010981-23 0012
Patents
No Patents information available for 5P01HD010981-23 0012
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01HD010981-23 0012
Clinical Studies
No Clinical Studies information available for 5P01HD010981-23 0012
News and More
Related News Releases
No news release information available for 5P01HD010981-23 0012
History
No Historical information available for 5P01HD010981-23 0012
Similar Projects
No Similar Projects information available for 5P01HD010981-23 0012